Biogen Idec Inc.
14 Cambridge Center
Cambridge,
MA 02142
United States - Map
Phone: 617-679-2000
Fax: 617-679-2617
Web Site: http://www.idecpharm.com
| Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. Its products include AVONEX for the treatment of relapsing forms of multiple sclerosis (MS); RITUXAN for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s lymphomas, or B-cell NHLs; TYSABRI for the treatment of relapsing forms of MS; and FUMADERM, an immunomodulator for the treatment of severe psoriasis. The company’s other products under development include BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb/galiximab, a Phase III clinical product for relapsed or refractory NHL; Anti-CD23 MAb/lumiliximab, a Phase II/III clinical product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb/Ocrelizumab, a Phase III clinical product for the treatment of Rheumatoid Arthritis; and Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia. In addition, its preclinical stage products include Volociximab, CNF2024, Natalizumab, RAF (BIIB024), CNF3647, Anti CRIPTO, Anti IGF-1R, Daclizumab, CDP-323, BIIB014, Neublastin, Baminercept-alfa, Anti-TWEAK, anti-CD40L Fab, ADENTRI, Aviptadil, and Long acting rFactor IX. Biogen Idec has collaboration agreements with PDL BioPharma, Inc.; Sunesis Pharmaceuticals, Inc.; Vernalis plc; Vetter Pharma-Fertigung GmbH & Co. KG; Elan Corporation plc; Alnylam Pharmaceuticals, Inc.; UCB SA; Neurimmune SubOne AG; Cardiokine Biopharma LLC; and Schering AG. The company was founded in 1985 and is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. James C. Mullen , 50
Chief Exec. Officer, Pres |
$
3.09M |
$
7.05M | Dr. Phil Sharp Ph.D., 63
Co-Founder, Director, Member of Corp. Governance Committee and Member of Transaction Committee |
$
63.00K | N/A | Mr. Paul J. Clancy , 46
Chief Financial Officer and Exec. VP of Fin. |
$
654.00K | N/A | Dr. Cecil B. Pickett Ph.D., 62
Pres of R&D |
$
1.36M | N/A | Mr. Robert Hamm M.a., 56
Exec. VP of Pharmaceutical Operations & Technology |
$
670.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.49% Nasdaq 
0.27%
Profile
